Updates on Immune Modulators in Lung Cancer: Have We Met the Need?

https://img.medscapestatic.com/thumbnail_library/943953.jpg?interpolation=lanczos-none&resize=300:*

 

This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.

 

The goal of this activity is to increase clinicians' understanding of timmune modulators used in the management of patients with metastatic non-small cell lung cancer (NSCLC)

 

 

 

 

 

 

Learning Objectives:

  • Have increased knowledge regarding the mmune modulators being studied to treat patients with metastatic NSCLC (mNSCLC), including how they may manipulate the immune system to improve recognition of cancer cells, tumors, and metastases

  • Have increased knowledge regarding the ongoing immunotherapy clinical trials in the management of patients with mNSCLC

 

Approximate Time to Complete: 15 minutes

 

Credit Available: January 13, 2021 - January 13, 2022

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

 

Additional Resources for Clinicans from SITC:

Certificate in Cancer Immunotherapy

 

 

Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.25
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.25